Regions – Page 208 – pharmaceutical daily

March 31, 2017 Off

CARB-X funds Tetraphase Pharmaceuticals antibiotic research with $4M

Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, will fund research of Tetraphase Pharmaceuticals’s pipeline candidate TP-6076, a novel, synthetic, fluorocycline antibiotic candidate with $4 million.

March 31, 2017 Off

DBV, HUG and BioNet report results from Phase I study of pertussis vaccine

By Dino Mustafić

DBV Technologies, the Geneva University Hospitals (HUG) and BioNet-Asia have announced results from a Phase I trial assessing Viaskin rPT`s ability to boost immunity against pertussis by epicutaneously administering two doses of BioNet`s recombinant pertussis toxin.

March 31, 2017 Off

Canadian cannabis company Invictus MD starts trading on TSX

By Dino Mustafić

Invictus MD Strategies Corp.,Canada’s cannabis company, said Thursday it will move its shares from the Canadian Securities Exchange and be listed on TSX Venture Exchange, where it starts trading on March 31, 2017.

March 31, 2017 Off

J&J expect to close successful $30 billion Actelion tender offer in second quarter

By Dino Mustafić

Johnson & Johnson said its $30 billion tender offer for Swiss biotechnology company Actelion was successful, with the price of the offer being 280 per share for Actelion.

March 31, 2017 Off

Kiadis Pharma reports €1.1M loss for 2016

By Dino Mustafić

Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has reported its audited annual results for the year ended December 31, 2016.

March 31, 2017 Off

argenx kicks off phase II of immune thrombocytopenia treatment study

By Dino Mustafić

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, has started dosing of the first patient in a Phase II proof-of-concept study of ARGX-113 in patients with primary immune thrombocytopenia (ITP).

March 31, 2017 Off

Bosnia and Herzegovina to allow medical cannabis?

By Dino Mustafić

A representative in Bosnia and Herzegovina’s Federation Parliament, Dennis Gratz, from central left winged civil liberal party “Nasa Stranka” has innitiated legalisation of cannabis as a cure.

March 30, 2017 Off

Horizon Pharma issues notice of allowance from USPTO for its anti-inflammatory drug

By Dino Mustafić

Horizon Pharma, a biopharmaceutical company focused identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, has issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 15/180,173…

March 30, 2017 Off

Shire’s attention deficit hyperactivity disorder drug to sell in Japan

By Dino Mustafić

Shire’s partner in Japan, Shionogi & Co has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv, a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD), a common psychiatric disorder in children and adolescents.

March 30, 2017 Off

Mylan bags global rights to ColdEeze

By Dino Mustafić

Mylan has acquired the global rights to the Cold-Eeze brand cold remedy line from ProPhase Labs, Inc.